These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27960593)

  • 1. Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine.
    Demeulemeester M; Lavis N; Balthazar Y; Lechien P; Heijmans S
    Hum Vaccin Immunother; 2017 Apr; 13(4):889-894. PubMed ID: 27960593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study.
    Stuurman AL; Verstraeten T; De Schryver A
    Expert Rev Vaccines; 2017 Feb; 16(2):187-191. PubMed ID: 27882801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L; Vinnemeier CD; Meyer S; Witte K; Marx L; Theeß W; Burchard GD; Rolling T; Cramer JP
    Hum Vaccin Immunother; 2015; 11(10):2370-5. PubMed ID: 26114800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of a cell culture derived trivalent subunit inactivated influenza vaccine administered to healthy children and adolescents: A Phase III, randomized, multicenter, observer-blind study.
    Nolan T; Chotpitayasunondh T; Capeding MR; Carson S; Senders SD; Jaehnig P; de Rooij R; Chandra R
    Vaccine; 2016 Jan; 34(2):230-236. PubMed ID: 26643931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial.
    Arnou R; Eavis P; Pardo JR; Ambrozaitis A; Kazek MP; Weber F
    Hum Vaccin; 2010 Apr; 6(4):346-54. PubMed ID: 20372053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military.
    Gao D; Yang H; Deng B; Yin G; Song W; Zhang H; Li Y
    Hum Vaccin Immunother; 2016 Oct; 12(10):2634-2639. PubMed ID: 27348250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
    Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
    Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
    Dos Santos G; Nguyen BY; Damaso S; Godderis L; Martínez-Gómez X; Eckermann T; Loos H; Salamanca de la Cueva I; Shende V; Schmidt AC; Yeakey A
    Drug Saf; 2020 Mar; 43(3):265-279. PubMed ID: 31884676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
    N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
    Carter C; Houser KV; Yamshchikov GV; Bellamy AR; May J; Enama ME; Sarwar U; Larkin B; Bailer RT; Koup R; Chen GL; Patel SM; Winokur P; Belshe R; Dekker CL; Graham BS; Ledgerwood JE;
    PLoS One; 2019; 14(9):e0222178. PubMed ID: 31532789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.
    Arnou R; Icardi G; De Decker M; Ambrozaitis A; Kazek MP; Weber F; Van Damme P
    Vaccine; 2009 Dec; 27(52):7304-12. PubMed ID: 19849996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
    JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial.
    Beran J; Ambrozaitis A; Laiskonis A; Mickuviene N; Bacart P; Calozet Y; Demanet E; Heijmans S; Van Belle P; Weber F; Salamand C
    BMC Med; 2009 Apr; 7():13. PubMed ID: 19341446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.